Exclusive License and Development Agreement Signed by Avecho and Sandoz for the Commercialized Use of CBD for Insomnia in Australia
Avecho and Sandoz have signed an exclusive license and development agreement to commercialize CBD for use with insomnia in Australia.
Image | adobe.stock/MysteryShot
In a recent press release, Avecho Biotechnology Limited (Avecho) disclosed that they have entered into a 10 year license and development agreement with Sandoz Group AG (Sandoz) for the “commercial rights to Avecho’s Phase III cannabidiol (CBD) capsule for insomnia in Australia,” (1). Through the agreement, Avecho is able to retain the rights to commercialize the CBD capsule in “all other territories”. Sandoz has received a “first right of refusal” in these markets. Avecho hopes their CBD capsule could be the first pharmaceutical CBD product to be registered with the Therapeutic Goods Administration (TGA) as an over-the-counter medicine (2). Fresh Leaf Analytics in their Australian Medicinal Cannabis Market Report estimated that sales could potentially surpass more than $125 million per annum in Australia (1,3).
Out of this agreement, Sandoz will have exclusive commercial rights to Avecho’s CBD capsules to be used for insomnia within the country after an upfront licensing fee estimated at $3 million (2). Avecho will still be working on the products’ Phase III clinical trial, as well as funding the research. Once the trial is completed, Avecho and Sandoz will work together to obtain TGA regulatory approval. From there, Sandoz will pay for the finished product from Avecho and take over handling it’s commercialization which will include both distribution, as well as marketing in Australia. According to the press release, Avecho will be eligible for development milestone payments estimated at $16 million before commercialization and will then be receiving tiered royalties which could range between 14% to 19% on net sales once the product has hit the market (2).
“We are excited to announce this partnership with Sandoz, which underscores the commercial potential of Avecho’s drug delivery platform and our shared commitment to deliver innovative insomnia treatments,” Dr Paul Gavin, CEO of Avecho, said (1,2). “Sandoz’s extensive reach and expertise in the Australian market will ensure our products are widely accessible to insomnia patients across Australia. This partnership provides Avecho with a strong commercial foundation for success.”
As mentioned in the press release, the agreement between the two companies is set for 10 years but will have automatic extensions for two renewal terms of two years each (1). The agreement will not renew if it is terminated by both companies.
References
- Avecho and Sandoz enter exclusive license and Development Agreement to commercialise CBD for insomnia in Australia https://avecho.com.au/investor-centre/news/2025/03/03/avecho-and-sandoz-enter-exclusive-license-and-development-agreement-to-commercialise-cbd-for-insomnia-in-australia/ (accessed Mar 3, 2025).
- Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02920239-3A663194 (accessed Mar 3, 2025).
- Fresh Leaf Analytics, Australian Medicinal Cannabis Market, H1 2021.
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
